The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials.
This review examines all randomized studies that evaluated the role of taxanes in the neoadjuvant treatment of breast cancer and have reported results in terms of efficacy and tolerance. The primary objective of this review was to evaluate whether, at this point in time, there is sufficient evidence to support the routine use of taxanes in the neoadjuvant treatment of breast cancer. Other objectives were to determine the optimal schedule in which to administer taxanes and anthracyclines and whether the addition of other antitumor drugs improves the efficacy of these anthracycline/taxane-based schedules. A literature search revealed 9 major randomized clinical trials published to date. To facilitate analysis, they were classified according to their protocol design. Five trials evaluated the effect of the addition of a taxane to an anthracycline-based schedule, either concomitantly or sequentially. The remaining 4 trials contained taxanes in both treatment arms in an attempt to optimize the administration schedule of anthracyclines and taxanes, or to improve efficacy by adding a further antitumor drug. This type of analysis has provided the opportunity to draw some conclusions regarding the optimal use of taxanes.
Tusquets
Ignasi
I
Hospital del Mar-IMAS, Barcelona, Spain. itusquets@imas.imim.es
Estévez
Laura G
LG
Alvarez
Isabel
I
Muñoz
Montserrat
M
Adrover
Encarna
E
Albanell
Joan
J
Rodríguez
César
C
Seguí
Miguel Angel
MA
Rodríguez-Lescure
Alvaro
A
Ruiz-Borrego
Manuel
M
García-Mata
Jesús
J
Lluch
Ana
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D043823:Taxoids / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D043823:Taxoids